Q-Line Biotech Limited

Discussion on Result of Operations

The following discussion on results of operations should be read in conjunction with the Restated Financial Statements for the years ended on March 31, 2025, March 31, 2024, and March 31, 2023.

(â‚¹ In Lakhs)

<table><thead><tr><th rowspan="2">PARTICULARS</th><th colspan="6">For the Year ended on</th></tr><tr><th colspan="2">31-03-2025</th><th colspan="2">31-03-2024</th><th colspan="2">31-03-2023</th></tr></thead><tbody><tr><td>1 Revenue From Operation</td><td>31,378.04</td><td>97.27%</td><td>20,364.61</td><td>98.64%</td><td>18,273.63</td><td>98.88%</td></tr><tr><td>2 Other Income</td><td>880.38</td><td>2.73%</td><td>280.2</td><td>1.36%</td><td>207.52</td><td>1.12%</td></tr><tr><td>3 Total Income (1+2)</td><td>32,258.42</td><td>100.00%</td><td>20,644.81</td><td>100.00%</td><td>18,481.15</td><td>100.00%</td></tr><tr><td>4 Expenditure</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(a) Cost of Material Consumed</td><td>5,762.05</td><td>17.86%</td><td>1,634.74</td><td>7.92%</td><td>908.03</td><td>4.91%</td></tr><tr><td>(b) Purchases of Stock-in trade</td><td>6,372.75</td><td>19.76%</td><td>10,468.19</td><td>50.71%</td><td>8,387.09</td><td>45.38%</td></tr><tr><td>(c) Changes in inventories of Stock in trade, WIP & Finished Goods</td><td>2,432.18</td><td>7.54%</td><td>-2,800.98</td><td>-13.57%</td><td>-448.57</td><td>-2.43%</td></tr><tr><td>(d) Employee Benefit Expenses</td><td>3,031.59</td><td>9.40%</td><td>2,348.63</td><td>11.38%</td><td>2,368.26</td><td>12.81%</td></tr><tr><td>(e ) Finance Cost</td><td>1,470.00</td><td>4.56%</td><td>627.52</td><td>3.04%</td><td>379.6</td><td>2.05%</td></tr><tr><td>(f) Depreciation and Amortisation Expenses</td><td>732.12</td><td>2.27%</td><td>392.77</td><td>1.90%</td><td>213.75</td><td>1.16%</td></tr><tr><td>(g) Other Expenses</td><td>6,341.96</td><td>19.66%</td><td>4,913.78</td><td>23.80%</td><td>3,688.99</td><td>19.96%</td></tr><tr><td>5 Total Expenditure 4(a) to 4(g)</td><td>26,142.66</td><td>81.04%</td><td>17,584.65</td><td>85.18%</td><td>15,497.15</td><td>83.85%</td></tr><tr><td>6 Profit/(Loss) Before Exceptional & extraordinary items & Tax (3-5)</td><td>6,115.75</td><td>18.96%</td><td>3,060.17</td><td>14.82%</td><td>2,984.01</td><td>16.15%</td></tr><tr><td>7 Extra-Ordinary Item</td><td>1,696.52</td><td>5.26%</td><td>0</td><td>0.00%</td><td>0</td><td>0.00%</td></tr><tr><td>8 Profit/(Loss) Before Tax (6-7)</td><td>4,419.23</td><td>13.70%</td><td>3,060.17</td><td>14.82%</td><td>2,984.01</td><td>16.15%</td></tr><tr><td>9 Tax Expense:</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(a) Tax Expense for Current Year</td><td>2,008.17</td><td>6.23%</td><td>883.01</td><td>4.28%</td><td>858.16</td><td>4.64%</td></tr><tr><td>(b) Short/(Excess) Provision of Earlier Year</td><td>0</td><td>0.00%</td><td>0</td><td>0.00%</td><td>0</td><td>0.00%</td></tr><tr><td>(c) Deferred Tax</td><td>-40.31</td><td>-0.12%</td><td>12.95</td><td>0.06%</td><td>-12.4</td><td>-0.07%</td></tr><tr><td>Net Current Tax Expenses</td><td>1,967.86</td><td>6.10%</td><td>895.96</td><td>4.34%</td><td>845.76</td><td>4.58%</td></tr><tr><td>10 Share of Profit(Loss) of-</td><td>361.71</td><td>1.12%</td><td>1,280.26</td><td>6.20%</td><td>1,071.46</td><td>5.80%</td></tr><tr><td>Associates</td><td>361.71</td><td>1.12%</td><td>1,280.26</td><td>6.20%</td><td>1,071.46</td><td>5.80%</td></tr><tr><td>12 Profit/(Loss) for the Year (8-9+10)</td><td>2,813.09</td><td>8.72%</td><td>3,444.47</td><td>16.68%</td><td>3,209.71</td><td>17.37%</td></tr><tr><td>13 Profit/(Loss) attributable to Minority Interest</td><td>0</td><td>0.00%</td><td>-0.45</td><td>0.00%</td><td>0</td><td>0.00%</td></tr><tr><td>14 Profit attributable to Parent Equity Shareholders (12-13)</td><td>2,813.09</td><td>8.72%</td><td>3,444.92</td><td>16.69%</td><td>3,209.71</td><td>17.37%</td></tr></tbody></table>

250